Frazier Life Sciences Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Frazier Life Sciences Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-600,000	Closed	-$8.71M	–	55
2023 Q3	$8.71M	Sell	600,000 -3,108,838	-84%	-$58.8M	0.58%	32
2023 Q2	$77.6M	Hold	3,708,838	–	–	4.64%	8
2023 Q1	$78.3M	Hold	3,708,838	–	–	5.67%	6
2022 Q4	$94.4M	Buy	3,708,838 +296,000	+9%	+$6.9M	5.87%	6
2022 Q3	$82M	Buy	3,412,838 +217,435	+7%	+$4.88M	6.31%	5
2022 Q2	$61.5M	Hold	3,195,403	–	–	5.8%	6
2022 Q1	$55.5M	Buy	+3,195,403	New	+$53.8M	4.73%	8

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Frazier Life Sciences Management's SNDX Position: Q4 2023 in Review

Frazier Life Sciences Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 600,000 shares — an estimated $8.71M sold.

Frazier Life Sciences Management first reported a position in SNDX in Q1 2022 and held it in 7 quarters. The position peaked at $94.4M in Q4 2022. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

Frazier Life Sciences Management reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Frazier Life Sciences Management sold 600,000 Syndax Pharmaceuticals shares in Q4 2023, an estimated $8.71M.
Frazier Life Sciences Management first reported a position in Syndax Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Frazier Life Sciences Management's Syndax Pharmaceuticals position peaked at $94.4M in Q4 2022.
177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.